Winslow Evans & Crocker’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Winslow Evans & Crocker’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$16K	Buy	+491	New	+$14.7K	﹤0.01%	842

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LWPC

Legacy Wealth Partners (California) Calabasas, California $180M AUM 48.85% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Winslow Evans & Crocker's CNCR Position: Q4 2020 in Review

Winslow Evans & Crocker opened a new position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2020: 491 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #842 among its holdings.

22 funds tracked by Wall St. Rank hold CNCR as of Q4 2020.

Winslow Evans & Crocker held 491 shares of ETF Series Solutions Trust Range Cancer Therapeutics ETF worth $16K as of Q4 2020.
ETF Series Solutions Trust Range Cancer Therapeutics ETF was a new Winslow Evans & Crocker position in Q4 2020.
ETF Series Solutions Trust Range Cancer Therapeutics ETF made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #842 holding.
22 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.